BWAYBrainsway Ltd

Quick Summary

BrainsWay Ltd. is an Israel-based medical technology company that develops, markets, and sells noninvasive neurostimulation systems for mental health and neurological disorders. The company is best known for its Deep Transcranial Magnetic Stimulation, or Deep TMS, platform, which is designed to stimulate targeted brain regions without surgery or systemic drug exposure. Its solutions are used primarily in psychiatry and behavioral health settings, especially for patients who have not achieved adequate improvement from medication or psychotherapy. BrainsWay sells mainly to physicians, psychiatric practices, hospitals, medical centers, and treatment clinics in the United States, Europe, Israel, and other international markets. The company operates in the medical equipment industry and generates revenue from the placement, sale, and utilization of its FDA-cleared Deep TMS systems and related treatment protocols.

Key Risks

• BrainsWay faces regulatory, reimbursement, competitive, and execution risks that could harm future performance.
• If payers restrict coverage, reduce reimbursement rates, or impose new documentation requirements, provider economics and patient access could weaken.
• Competing TMS and neuromodulation companies such as Neuronetics, MagVenture, Nexstim, and Magstim may pressure pricing, win clinic placements, or introduce new technologies.
• The Neurolief investment carries uncertainty because Proliv Rx is awaiting FDA approval and may not achieve regulatory clearance, commercial adoption, or expected clinical outcomes.

What to Watch

Price Drivers

• BrainsWay’s stock price is likely driven by revenue growth, profitability, system placement trends, and utilization of its Deep TMS platform.
• The company reported operating revenue of about $52.2 million, net income of about $7.6 million, basic EPS of $0.20, and diluted EPS of $0.18, which suggests investors are watching whether profitability can scale.
• Valuation is another major driver because the shares trade at a relatively high price-to-earnings multiple near 38.7 and an EV-to-EBITDA multiple above 46, leaving limited room for disappointment.
• Reimbursement policy is especially important, as Evernorth Behavioral Health’s decision to remove prior authorization for TMS for eligible patients could increase treatment access and improve utilization.

Recent News

• BrainsWay recently invested $5 million in Neurolief, gaining strategic exposure to at-home mental health treatment through a wearable neuromodulation device called Proliv Rx.
• Neurolief’s device is being developed for treatment-resistant major depressive disorder and is awaiting FDA approval, so the investment could expand BrainsWay beyond clinic-based Deep TMS if milestones are achieved.
• BrainsWay also welcomed Evernorth Behavioral Health’s decision to eliminate prior authorization requirements for TMS for eligible contracted providers treating Evernorth and Cigna Healthcare members.
• The company announced peer-reviewed data for its SWIFT accelerated Deep TMS protocol, reporting high response and remission rates while reducing treatment time compared with standard schedules.

Market Trends

• The broader TMS and neuromodulation market is benefiting from rising awareness of depression, OCD, Parkinson’s disease, migraine, Alzheimer’s disease, and other neurological or psychiatric conditions.
• Market research cited in recent news estimates the global TMS market could grow from roughly $1.1 billion to between $1.7 billion and $2.0 billion over the coming years, depending on the forecast period.
• North America remains a leading market because of established reimbursement systems, higher mental health treatment spending, and greater adoption of device-based therapies.
• Asia-Pacific is expected to grow quickly as healthcare infrastructure, diagnosis rates, and demand for noninvasive treatment options increase.